INFUSYSTEM HOLDINGS, INC Business Acquisition, Pro Forma Revenue
INFUSYSTEM HOLDINGS, INC (INFU) reported Business Acquisition, Pro Forma Revenue of $103.15 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-16.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2023-03-16
- INFUSYSTEM HOLDINGS, INC business acquisition, pro forma revenue for the quarter ending 2021-12-31 was $26.52M, a 7.10% increase year-over-year.
- INFUSYSTEM HOLDINGS, INC business acquisition, pro forma revenue for the quarter ending 2021-09-30 was $26.57M, a 3.25% increase year-over-year.
- INFUSYSTEM HOLDINGS, INC business acquisition, pro forma revenue for the quarter ending 2021-06-30 was $25.39M, a 5.39% decline year-over-year.
- INFUSYSTEM HOLDINGS, INC business acquisition, pro forma revenue for the quarter ending 2021-03-31 was $24.68M.
- INFUSYSTEM HOLDINGS, INC business acquisition, pro forma revenue for fiscal 2021 was $103.15M, a 3.12% increase from fiscal 2020.
- INFUSYSTEM HOLDINGS, INC business acquisition, pro forma revenue for fiscal 2020 was $100.03M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $26.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $53.09M derived: sum of 2 quarters · filed 2023-03-16 | $78.47M derived: sum of 3 quarters · filed 2023-03-16 | $103.15M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $26.57M 10-Q · filed 2022-11-08 | $51.95M derived: sum of 2 quarters · filed 2022-11-08 | $76.63M 10-Q · filed 2022-11-08 | $101.39M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2021-06-30 | $25.39M 10-Q · filed 2022-08-04 | $25.04M 10-Q · filed 2021-08-12 | $50.07M 10-Q · filed 2022-08-04 | $74.83M derived: sum of 3 quarters · filed 2023-03-16 | $100.56M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $24.68M 10-Q · filed 2022-05-05 | $49.44M derived: sum of 2 quarters · filed 2023-03-16 | $75.17M derived: sum of 3 quarters · filed 2023-03-16 | $102.01M derived: sum of 4 quarters · filed 2023-03-16 | |
| 2020-12-31 | $24.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $50.49M derived: sum of 2 quarters · filed 2023-03-16 | $77.33M derived: sum of 3 quarters · filed 2023-03-16 | $100.03M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $25.73M 10-Q · filed 2021-11-15 | $52.57M derived: sum of 2 quarters · filed 2021-11-15 | $75.27M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $26.84M 10-Q · filed 2021-08-12 | $49.54M 10-Q · filed 2021-08-12 | |||
| 2015-09-30 | $18.69M 10-Q · filed 2015-11-12 | $36.26M derived: sum of 2 quarters · filed 2015-11-12 | $53.91M 10-Q · filed 2015-11-12 | ||
| 2015-06-30 | $17.57M 10-Q · filed 2015-08-13 | $35.09M 10-Q · filed 2015-08-13 | |||
| 2014-09-30 | $17.50M 10-Q · filed 2015-11-12 | $34.84M derived: sum of 2 quarters · filed 2015-11-12 | $52.88M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $17.34M 10-Q · filed 2015-08-13 | $35.55M 10-Q · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 |